Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

BHVN

Biohaven (BHVN)

Biohaven Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:BHVN
DateTimeSourceHeadlineSymbolCompany
05/17/20243:42PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
05/17/20243:41PMEdgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NYSE:BHVNBiohaven Ltd
05/09/20243:16PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:BHVNBiohaven Ltd
05/09/20243:14PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
05/09/20243:05PMPR Newswire (US)Biohaven Reports First Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
04/22/20243:05PMPR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
04/17/20243:05PMPR Newswire (US)Biohaven Announces Proposed Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
04/13/20248:00AMPR Newswire (US)Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business UpdatesNYSE:BHVNBiohaven Ltd
02/29/20243:16PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
02/29/20243:05PMPR Newswire (US)Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
01/08/20246:30AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
01/08/20246:30AMPR Newswire (US)Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and OncoloNYSE:BHVNBiohaven Ltd
01/02/20246:00AMPR Newswire (US)Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:BHVNBiohaven Ltd
12/01/20233:30PMPR Newswire (US)Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingNYSE:BHVNBiohaven Ltd
11/14/20233:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
11/14/20233:05PMPR Newswire (US)Biohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
10/16/20236:00AMPR Newswire (US)Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®NYSE:BHVNBiohaven Ltd
10/05/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
10/05/20233:05PMPR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
10/04/20233:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
10/02/202310:56PMPR Newswire (US)Biohaven Announces Pricing of $225 Million Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
10/02/20238:41PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
10/02/20234:09PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
10/02/20234:07PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
10/02/20233:36PMPR Newswire (US)BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARESNYSE:BHVNBiohaven Ltd
10/02/20233:01PMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:BHVNBiohaven Ltd
09/27/20235:58AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
09/14/20236:00AMPR Newswire (US)Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular AtrophyNYSE:BHVNBiohaven Ltd
09/05/20236:00AMPR Newswire (US)Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal StudiesNYSE:BHVNBiohaven Ltd
07/31/20234:18PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
 Showing the most relevant articles for your search:NYSE:BHVN